Rocket Lab Jumped 8% on its 17th Electron Launch of the…

Rocket Lab USA (NASDAQ: RKLB) closed at $69.89 on 21 September, up 8.24%, recovering from a 4.8% drop on 18 September that followed a $1.94 billion equity raise to fund its Iridium Communications acquisition. The rebound was driven by the company's 96th Electron mission, launched on 19 September for repeat customer Synspective, and a reiterated $122 price target from Cantor Fitzgerald.

Mission 96 and the Synspective Backlog

The mission, named "Owl By The Dozen," lifted Synspective's 12th StriX synthetic aperture radar (SAR) satellite to a 572-kilometre low Earth orbit from Launch Complex 1 in Mahia, New Zealand. It marked Rocket Lab's 17th Electron launch of 2026 and extended a 100% mission success record with the Japanese radar-imaging company, according to the company's investor release. Synspective has 15 additional dedicated Electron missions booked through the end of the decade to complete its commercial SAR constellation. That single-customer backlog provides a revenue floor for Rocket Lab's small-launch division at a time when the company's total backlog stands at $2.36 billion, up 137% year-on-year, with more than 90 missions queued across all customers.

Cantor's $122 Target vs. the $109 Consensus

Cantor Fitzgerald analyst Andres Sheppard reiterated an Overweight rating and a $122 price target on 21 September, roughly 75% above the closing price. Sheppard argued that Rocket Lab is positioned as "the only viable alternative and most direct commercial competitor to SpaceX's Falcon 9 once operational," citing the upcoming Neutron medium-lift rocket and the Iridium acquisition as catalysts.The consensus among 20 analysts tracked by Stock Analysis sits at approximately $109.37, with 16 of 20 rating the stock a Buy or Strong Buy and none issuing a Sell.Targets range from $64 to $150. Cantor's $122 sits above the median but well within the bull-case range, and it is a reiteration rather than an upgrade, a distinction worth noting: the view has not changed, even after a 19% seven-session slide in late August erased roughly $10 billion of market value.

Neutron and Iridium Remain the Real Catalysts

The tension in Rocket Lab's valuation is that Electron, for all its launch cadence, is not what justifies a $122 target. Cantor models that the Iridium deal will roughly double annual revenue once it closes, expected by mid-2027. The firm also projects that Neutron's target average selling price of $50 million to $55 million per launch could make Rocket Lab the only listed company operating at the scale needed to compete with SpaceX, which commands 80% to 90% of total mass delivered to orbit annually.Execution risks remain, as Rocket Lab posted Q2 revenue of $234.07 million, up 62% year-on-year, with a non-GAAP gross margin of 41.5% and Q3 guidance of $250 million to $265 million. Those are strong numbers, but the company remains unprofitable on a GAAP basis, and the $1.94 billion equity raise that weighed on the 18 September selloff will dilute existing shareholders.Neutron's first flight is targeted for late 2026, and any further delay could test the patience of investors who have already absorbed a $10 billion drawdown in seven sessions as recently as late August.Neutron's debut and the Iridium close are the next two events that will determine whether RKLB is a $40 stock or a $120 one. Until both arrive, the Electron cadence keeps the operational story intact while the market waits.